Literature DB >> 11985637

Decrease in heart ventricular ejection fraction during multiple sclerosis.

S Olindo1, B Guillon, J Helias, B Phillibert, C Magne, J R Fève.   

Abstract

Recent studies have shown that mitoxantrone is effective in patients with active multiple sclerosis (MS) and that cardiac monitoring is usually required. However, right and left ventricular ejection fractions (VEFs) have never been studied in MS patients as compared with control subjects. Radionuclide angiocardiography (RA) was performed to assess right and left VEFs at rest in 40 consecutive patients with active definite MS [15 men and 25 women; mean age 33.9 +/- 10 years; mean disease duration 8 +/- 6.5 years; 18 had relapsing-remitting and 22 had secondary progressive forms of the disease; mean Expanded Disability Status Scale (EDSS) score 4.8 +/- 1.9]. The control group consisted of 40 subjects free of neurological or cardiovascular disease (17 men and 23 women; 44.6 +/- 13.4 years of age). The VEF values obtained in the control group defined the normal limits (right VEF 32-54%; left VEF 50-74%). A statistically significant decrease of right (P=0.02) and left (P < 0.0001) VEFs was found in MS patients as compared with control subjects. RA showed pathological results for right (7.5%), left (10%) and both (7.5%) VEFs in 25% of MS patients. No correlation was found between VEF and sex, age, disease duration, disease course, EDSS score or previous treatment. Autonomic impairment, which frequently occurs in MS patients, may have accounted for the decrease in VEFs. Further physiological studies are required to determine factor responsible for the decrease of VEFs in MS.

Entities:  

Mesh:

Year:  2002        PMID: 11985637     DOI: 10.1046/j.1468-1331.2002.00400.x

Source DB:  PubMed          Journal:  Eur J Neurol        ISSN: 1351-5101            Impact factor:   6.089


  5 in total

1.  Usefulness of myocardial performance index in multiple sclerosis mitoxantrone-induced cardiotoxicity.

Authors:  Paolo Pattoneri; Giovanna Pelà; Enrico Montanari; Ilaria Pesci; Paolo Moruzzi; Alberto Montanari
Journal:  Heart Asia       Date:  2012-01-01

2.  Severe delayed heart failure in three multiple sclerosis patients previously treated with mitoxantrone.

Authors:  Sophie Goffette; Vincent van Pesch; Jean Louis Vanoverschelde; Emmanuel Morandini; Christian J M Sindic
Journal:  J Neurol       Date:  2005-04-18       Impact factor: 4.849

3.  Cardiotoxicity and other adverse events associated with mitoxantrone treatment for MS.

Authors:  E Kingwell; M Koch; B Leung; S Isserow; J Geddes; P Rieckmann; H Tremlett
Journal:  Neurology       Date:  2010-04-28       Impact factor: 9.910

Review 4.  Painful and involuntary multiple sclerosis.

Authors:  Francesca Bagnato; Diego Centonze; Simonetta Galgani; Maria Grazia Grasso; Shalom Haggiag; Stefano Strano
Journal:  Expert Opin Pharmacother       Date:  2011-02-17       Impact factor: 3.889

Review 5.  Cardiac Autonomic Dysfunction in Multiple Sclerosis: A Systematic Review of Current Knowledge and Impact of Immunotherapies.

Authors:  Oliver Findling; Larissa Hauer; Thomas Pezawas; Paulus S Rommer; Walter Struhal; Johann Sellner
Journal:  J Clin Med       Date:  2020-01-24       Impact factor: 4.241

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.